

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A method of treating rheumatoid arthritis, comprising administering to a mammal in need thereof effective amounts of an anti-CD11a antibody and a TNF- α antagonist wherein the TNF- α antagonist is a TNF- α receptor - IgG Fc fusion protein.
- 2-5. (Canceled)
6. (Previously presented) The method of claim 1, wherein the anti-CD11a antibody is a non T-cell depleting antibody.
7. (Presently canceled) The method of claim 1, wherein the TNF- α antagonist is an immunoadhesin.
8. (Presently canceled) The method of claim 7, wherein the immunoadhesin is a fusion of at least a TNF- α binding portion of a TNF- α receptor and an immunoglobulin constant domain sequence.
9. (Presently canceled) The method of claim 8, wherein the immunoadhesin is a TNF- α receptor - IgG Fc fusion protein.
- 10-17. (Cancelled)
18. (Currently amended) The method of claim [[9]] 1, wherein the fusion protein consists of the extracellular ligand binding portion of human tumor necrosis factor receptor linked to the hinge region, CH2 and CH3 domains of human IgG1.
19. (Currently amended) The method of claim 1 or claim 18, further comprising administering to the mammal an effective amount of methotrexate.
20. (Previously presented) The method of claim 1 ~~or claim 9~~, wherein the anti-CD11a antibody is a humanized antibody.
21. (Withdrawn) The method of claim 1, wherein the TNF- α antagonist is an anti-TNF- α antibody.

Appl. no. 09/738,540
Amdt. dated 7/11/2003
Reply to Office action of 2/11/03

22. (Withdrawn) The method of claim 21, wherein the anti-TNF- α antibody is a chimeric monoclonal antibody.
23. (Withdrawn) The method of claim 21, wherein the anti-TNF- α antibody is a human or humanized monoclonal antibody.
24. (Previously presented) The method of claim 18, wherein the anti-CD11a antibody and fusion protein are administered sequentially.
25. (Previously presented) The method of claim 18, wherein the anti-CD11a antibody and fusion protein are administered concurrently.